Zacks: Analysts Expect Eagle Pharmaceuticals (EGRX) Will Announce Earnings of $0.84 Per Share

Equities research analysts expect Eagle Pharmaceuticals (NASDAQ:EGRX) to post earnings per share of $0.84 for the current quarter, according to Zacks. Two analysts have issued estimates for Eagle Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $1.11 and the lowest estimate coming in at $0.57. Eagle Pharmaceuticals posted earnings of $1.42 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 40.8%. The firm is expected to issue its next quarterly earnings results on Monday, May 14th.

According to Zacks, analysts expect that Eagle Pharmaceuticals will report full year earnings of $3.87 per share for the current year, with EPS estimates ranging from $3.68 to $4.06. For the next year, analysts expect that the business will post earnings of $4.25 per share, with EPS estimates ranging from $3.96 to $4.53. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Eagle Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its earnings results on Monday, February 26th. The specialty pharmaceutical company reported $0.84 EPS for the quarter, missing the consensus estimate of $1.00 by ($0.16). The company had revenue of $46.80 million for the quarter, compared to analyst estimates of $53.65 million. Eagle Pharmaceuticals had a return on equity of 34.16% and a net margin of 21.94%. The firm’s revenue was down 42.3% on a year-over-year basis. During the same period last year, the business earned $3.52 earnings per share.

EGRX has been the topic of several analyst reports. Zacks Investment Research lowered Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, March 1st. Piper Jaffray reaffirmed a “buy” rating and set a $79.00 target price on shares of Eagle Pharmaceuticals in a report on Tuesday, January 30th. Mizuho reaffirmed an “underperform” rating and set a $40.00 target price (up from $37.00) on shares of Eagle Pharmaceuticals in a report on Wednesday, March 21st. ValuEngine lowered Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Finally, BidaskClub lowered Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 18th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Eagle Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $63.33.

Eagle Pharmaceuticals stock traded up $0.41 during midday trading on Thursday, hitting $53.97. 69,184 shares of the company were exchanged, compared to its average volume of 239,605. The firm has a market cap of $778.92, a price-to-earnings ratio of 15.98 and a beta of 1.38. Eagle Pharmaceuticals has a fifty-two week low of $45.05 and a fifty-two week high of $97.15. The company has a quick ratio of 3.88, a current ratio of 3.99 and a debt-to-equity ratio of 0.24.

In other Eagle Pharmaceuticals news, Director Sander A. Flaum sold 2,340 shares of the stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $53.94, for a total transaction of $126,219.60. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 19.50% of the company’s stock.

A number of hedge funds have recently modified their holdings of EGRX. Municipal Employees Retirement System of Michigan boosted its position in Eagle Pharmaceuticals by 68.1% during the third quarter. Municipal Employees Retirement System of Michigan now owns 3,210 shares of the specialty pharmaceutical company’s stock worth $191,000 after purchasing an additional 1,300 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Eagle Pharmaceuticals by 6.8% in the third quarter. Rhumbline Advisers now owns 17,076 shares of the specialty pharmaceutical company’s stock valued at $1,018,000 after acquiring an additional 1,080 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Eagle Pharmaceuticals by 15.2% in the third quarter. Bank of New York Mellon Corp now owns 134,277 shares of the specialty pharmaceutical company’s stock valued at $8,008,000 after acquiring an additional 17,767 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Eagle Pharmaceuticals by 60.8% in the third quarter. SG Americas Securities LLC now owns 4,511 shares of the specialty pharmaceutical company’s stock valued at $269,000 after acquiring an additional 1,706 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its position in shares of Eagle Pharmaceuticals by 4.2% in the third quarter. Ameriprise Financial Inc. now owns 138,619 shares of the specialty pharmaceutical company’s stock valued at $8,267,000 after acquiring an additional 5,548 shares in the last quarter.

WARNING: “Zacks: Analysts Expect Eagle Pharmaceuticals (EGRX) Will Announce Earnings of $0.84 Per Share” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.chaffeybreeze.com/2018/04/17/zacks-analysts-expect-eagle-pharmaceuticals-egrx-will-announce-earnings-of-0-84-per-share.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply